Advanced search
Publication Cover
Expert Review of Clinical Pharmacology Volume 7, 2014 - Issue 1
Submit an article Journal homepage
402
Views
20
CrossRef citations to date
0
Altmetric
Reviews

Novel therapeutic options for multiple sclerosis

François CurtinGeNeuro SA, Chemin des Aulx 18, CH-1228 Plan-les-Ouates/Geneva, SwitzerlandCorrespondence[email protected]
&
Hans-Peter HartungDepartment of Neurology and Center for Neuropsychiatry, Heinrich Heine University, Duesseldorf, Germany
Pages 91-104 | Published online: 10 Dec 2013

References

  • McFarland HF, Martin R. Multiple sclerosis: a complicated picture of autoimmunity. Nat. Immunol. 8(9), 913–919 (2007).
  • Sadiq SA. Multiple sclerosis. In: Merrit’s Neurology. Rowland LP ( Ed.). Lippincott, William & Wilkins, Philadelphia, PA, USA (2005).
  • Lassmann H, Brück W, Lucchinetti CF. The immunopathology of multiple sclerosis: an overview. Brain Pathol. 17, 210–208 (2007).
  • Ciccone A, Beretta S, Brusaferri F, Galea I, Protti A, Spreafico C. Corticosteroids for the long-term treatment in multiple sclerosis. Cochrane Database Syst. Rev. 1, CD006264 (2008).
  • Casetta I, Iuliano G, Filippini G. Azathioprine for multiple sclerosis. Cochrane Database Syst. Rev. 4, CD003982 (2007).
  • Patti F, Lo Fermo S. Lights and shadows of cyclophosphamide in the treatment of multiple sclerosis. Autoimmune Dis. 2011, 961702 (2011).
  • Spain RI, Cameron MH, Bourdette D. Recent developments in multiple sclerosis therapeutics. BMC Med. 7, 74 (2009).
  • PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 352(9139), 1498–1504 (1998).
  • La Mantia L, Vacchi L, Di Pietrantoni C et al. Interferon beta for secondary progressive multiple sclerosis. Cochrane Database Syst. Rev. 1, CD005181 (2012).
  • Reuss R. PEGylated interferon beta-1a in the treatment of multiple sclerosis - an update. Biologics 7, 131–138 (2013).
  • Kala M, Miravalle A, Vollmer T. Recent insights into the mechanism of action of glatiramer acetate. J. Neuroimmunol. 235(1–2), 9–17 (2011).
  • Johnson KP, Brooks BR, Cohen JA et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 45(7), 1268–1276 (1995).
  • O’Connor P, Filippi M, Arnason B et al. 250 microgr or 500 microgr interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, radomised, multicenter study. Lancet Neurol. 8(10), 889–897 (2009).
  • Mikol DD, Barkhof F, Chang P et al. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the Rebif vs Glatiramer Acetate in relapsing MS disease REGARD study): a multicentre, randomized, parallel, open-label trial. Lancet Neurol. 7(10), 903–914 (2008).
  • Martinelli Boneschi F, Vacchi L, Rovaris M, Capra R, Comi G. Mitoxantrone for multiple sclerosis. Cochrane Database Syst Rev. 5, CD002127 (2013).
  • Polman CH, O’Connor PW, Havrdova E et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. 354(9), 899–910 (2006).
  • Brinkmann V, Billich A, Baumruker T et al. Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. Nat. Rev. Drug Discov. 9(11), 883–897 (2010).
  • Chun J, Hartung HP. Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis. Clin. Neuropharmacol. 33(2), 91–101 (2010).
  • Groves A, Kihara Y, Chun J. Fingolimod: direct CNS effects of sphingosine 1-phosphate (S1P) receptor modulation and implications in multiple sclerosis therapy. J. Neurol. Sci. 328(1–2), 9–18 (2013).
  • Kappos L, Radue EW, O’Connor P et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N. Engl. J. Med. 362(5), 387–401 (2010).
  • Cohen JA, Barkhof F, Comi G et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N. Engl. J. Med. 362(5), 402–415 (2010).
  • Calabresi PA, Goodin D, Jeffery D et al. Efficacy and safety of fingolimod versus placebo: primary outcomes from the phase 3 FREEDOMS II study in patients with relapsing-remitting multiple scelrosis. Presented at: 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Lyon, France, 10–13 October 2012 ( Abstract P491).
  • Kuehn BM. FDA notes rare infection in patient who took fingolimod for MS. JAMA 310(16), 1666 (2013).
  • Cohen JA, O’Connor P, Caliolio T et al. Long-term safety of fingolimod in relapsing multiple sclerosis. Update to integrated analyses of phase 2 and 3 studies and extension phases. Presented at: 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Lyon, France, 10–13 October 2012 ( Abstract P983).
  • Miller D, Cree B, Dalton C et al. Study design and baseline characteristics of the INFORMS Study: fingolimod in patients with primary progressive multiple sclerosis. Presented at: 65th American Academy of Neurology Annual Meeting. San Diego, CA, USA, 16–23 March 2013 ( P07.116).
  • O’Connor P, Wolinsky JS, Confavreux C et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N. Engl. J. Med. 365(14), 1293–1303 (2011).
  • Kappos L, Comi G, Confavreux et al. The efficacy and safety of teriflunomide in patients with relapsing MS: results from TOWER, a phase III placebo-controlled study. Presented at: 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Lyon, France, 10–13 October 2012 ( Abstract P153).
  • Comi G, Benzerdjeb H, Wang L, Truffinet P, O’Connor P. Effect of teriflunomide on lymphocyte and neutrophil levels in patients with relapsing multiple sclerosis: results from the TEMSO study. Presented at: 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Lyon, France, 10–13 October 2012 ( Abstract P995).
  • Kieseier B, Stüve O, Benamor M et al. Updated pregnancy outcomes from the teriflunomide clinical development programme: retrospective analysis of the teriflunomide clinical trial database. Presented at: 29th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Copenhagen, Denmark, 2–5 October 2013 ( Abstract P541).
  • Ropper AH. The poison chair treatment for multiple sclerosis. N. Engl. J. Med. 367(12), 1149–1150 (2012).
  • Gold R, Kappos L, Arnold DL et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N. Engl. J. Med. 367(12), 1098–1107 (2012).
  • Fox RJ, Miller DH, Phillips JT et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N. Engl. J. Med. 367(12), 1087–1097 (2012).
  • Phillips JT, Fox RJ, Selmaj K et al. Safety profile of BG-12 (dimethyl fumarate) in relapsing remitting multiple sclerosis: long-term interim results from the ENDORSE extension study. Presented at: 29th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Copenhagen, Denmark, 2–5 October 2013 ( Abstract P996).
  • van Oosten BW, Killestein J, Barkhof F, Polman CH, Wattjes MP. PML in a patient treated with dimethyl fumarate from a compounding pharmacy. N. Engl. J. Med. 368(17), 1658–1659 (2013).
  • Ermis U, Weis J, Schulz JB. PML in a patient treated with fumaric acid. N. Engl. J. Med. 368(17), 1657–1658 (2013).
  • Lehmann JC, Listopad JJ, Rentzsch CU et al. Dimethylfumarate induces immunosuppression via glutathione depletion and subsequent induction of heme oxygenase 1. J. Invest. Dermatol. 127(4), 835–845 (2007).
  • Coles AJ, Twyman CL, Arnold DL et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet 380(9856), 1829–1839 (2012).
  • Cohen JA, Coles AJ, Arnold DL et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet 380(9856), 1819–1828 (2012).
  • Coles AJ, Fox E, Vladic A et al. Alemtuzumab more effective than interferon β-1a at 5-year follow-up of CAMMS223 clinical trial. Neurology 78(14), 1069–1078 (2012).
  • Hartung HP, Arnold DL, Cohen JA et al. Reduction of disability with alemtuzumab in relapsing remitting multiple sclerosis patients who participated in CARE-MS II: three year follow-up. Presented at: 29th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Copenhagen, Denmark, 2–5 October 2013 ( Abstract P592).
  • Costelloe L, Jones J, Coles A. Secondary autoimmune diseases following alemtuzumab therapy for multiple sclerosis. Expert Rev. Neurother. 12(3), 335–341 (2012).
  • Cross AH, Klein RS. Comment: assessing humoral immunocompetence after alemtuzumab treatment in MS. Neurology 81(10), 875 (2013).
  • Chanvillard C, Jacolik RF, Infante-Duarte C, Nayak RC. The role of natural killer cells in multiple sclerosis and their therapeutic implications. Front. Immunol. 4, 63 (2013).
  • Wiendl H, Gross CC. Modulation of IL-2Rα with daclizumab for treatment of multiple sclerosis. Nat. Rev. Neurol. 9(7), 394–404 (2013).
  • Gold R, Giovannoni G, Selmaj K et al. Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial. Lancet 381(9884), 2167–2175 (2013).
  • Havrdova E, Gold R, Giovannoni G, Umans K, Glyman S, Elkins J. The effect of daclizumab HYP on sustained disability progression in the SELECT trial. Presented at: 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Lyon, France, 10–13 October 2012 ( Abstract P949).
  • Giovannoni G, Gold R, Selmaj K et al. Primary results of the SELECTION trial of daclizumab HYP in relapsing multiple sclerosis. Presented at: 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Lyon, France, 10–13 October 2012 ( Abstract P169).
  • Brück W, Wegner C. insight into the mechanism of laquinimod action. J. Neurol. Sci. 306(1–2), 173–179 (2011).
  • Comi G, Jeffery D, Kappos L et al. Placebo-controlled trial of oral laquinimod for multiple sclerosis. N. Engl. J. Med. 366(11), 1000–1009 (2012).
  • Nicholas J, Morgan-Followell B, Pitt D, Racke MK, Boster A. New and emerging disease-modifying therapies for relapsing-remitting multiple sclerosis: what is new and what is to come. J. Cent. Nerv. Syst. Dis. 4, 81–103 (2012).
  • Gergely P, Nuesslein-Hildesheim B, Guerini D et al. The selective sphingosine 1-phosphate receptor modulator BAF312 redirects lymphocyte distribution and has species-specific effects on heart rate. Br. J. Pharmacol. 167(5), 1035–1047 (2012).
  • Selmaj K, Li DK, Hartung HP et al. Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study. Lancet Neurol. 12(8), 756–767 (2013).
  • Li DKB, Hemmer B, Stuve O et al. Siponimod (BAF312) treatment leads to early MRI benefits in relapsing remitting multiple sclerosis patients: results from a phase 2 study. Presented at: 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Lyon, France, 10–13 October 2012 ( Abstract P494).
  • Hartung HP, Pigeolet E, Li D et al. The selective sphingosine 1-phosphate receptor modulator siponimod (BAF312): magnetic resonance imaging lesion and lymphocyte relationship in a phase 2 study in relapsing remitting multiple sclerosis. Presented at: 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Lyon, France, 10–13 October 2012 ( Abstract P934).
  • Hutas G. Ocrelizumab, a humanized monoclonal antibody against CD20 for inflammatory disorders and B-cell malignancies. Curr. Opin. Investig. Drugs 9(11), 1206–1215 (2008).
  • Fontoura P. Monoclonal antibody therapy in multiple sclerosis. mAbs 2(6), 670–681 (2010).
  • Meinl E, Krumbholz M, Hohlfeld R. B lineage cells in the inflammatory central nervous system environment: migration, maintenance, local antibody production, and therapeutic modulation. Ann. Neurol. 59(6), 880–892 (2006).
  • Kappos L, Li D, Calabresi PA, O’Connor P et al. Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet 378(9805), 1779–1787 (2011).
  • Kappos L, Leppert D, Tinbergen J, Gerber M, Hauser SL. Risk of infections and malignancies after treatment with anti-CD20 monoclonal antibodies:ocrelizumab abd rituximab in rheumatoid arthritis and multiple sclerosis. Presented at: 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Lyon, France, 10–13 October 2012 ( Abstract P929).
  • Rigby W, Tony HP, Oelke K et al. Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a forty-eight-week randomized, double-blind, placebo-controlled, parallel-group phase III trial. Arthritis Rheum. 64(2), 350–359 (2012).
  • Kappos L Li, D, Calabresi P, O’Connor P et al. Long-term safety and efficacy of ocrelizumab in patients with relapsing-remitting multiple scelrosis: week 144 results of a phase II randomized multicentre trial. Presented at: 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Lyon, France, 10–13 October 2012 ( Abstract P362).
  • Dubreuil P, Letard S, Ciufolini M et al. Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT. PLoS ONE 4(9), e7258 (2009).
  • Vermersch P, Benrabah R, Schmidt N et al. Masitinib treatment in patients with progressive multiple sclerosis: a randomized pilot study. BMC Neurol. 12, 36 (2012).
  • Kawamoto E, Nakahashi S, Okamoto T, Imai H, Shimaoka M. Anti-integrin therapy for multiple sclerosis. Autoimmune Dis. 2012, 357101 (2012).
  • Miller DH, Weber T, Grove R et al. Firategrast for relapsing remitting multiple sclerosis: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 11(2), 131–139 (2012).
  • Komiya T, Sato K, Shioya H et al. Efficacy and immunomodulatory actions of ONO-4641, a novel selective agonist for sphingosine 1-phosphate receptors 1 and 5, in preclinical models of multiple sclerosis. Clin. Exp. Immunol. 171(1), 54–62 (2013).
  • Bar-Or A, Zipp F, Krzysztof S, Due B, Vollmer T. Effect of the sphingosine 1-phosphate receptor agonist ONO-4641 on circulating lymphocytes in patients with relapsing–remitting multiple sclerosis: results from the Phase 2 DreaMS trial. Presented at: 65th American Academy of Neurology Annual Meeting. San Diego, CA, USA, 16–23 March 2013 ( Abstract P05.153).
  • Zipp F; Vollmer TL, Selmak KW, Bar-Or A; DreaMS Study Group. Efficacy and safety of the S1P receptor agonist ONO-4641 in patients with relapsing-remitting multiple sclerosis: results of a 26-week double blind placebo-controlled phase II trial (DreaMS). Presented at: 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Lyon, France, 10–13 October 2012 ( Abstract P482).
  • Piali L, Froidevaux S, Hess P et al. The selective sphingosine 1-phosphate receptor 1 agonist ponesimod protects against lymphocyte-mediated tissue inflammation. J. Pharmacol. Exp. Ther. 337(2), 547–556 (2011).
  • Olsson T, Boster O, Fernandez MS et al. Efficacy and safety of ponesimod, an oral, selective sphingosine 1-phosphate receptor-1 modulator, in patients with relapsing-remitting multiple sclerosis: results from a phase IIb, randomised, double-blind, placebo-controlled trial. Presented at: 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Lyon, France, 10–13 October 2012 ( Abstract P152).
  • Brossard P, Derendorf H, Xu J, Maatouk H, Halabi A, Dingemanse J. Pharmacokinetics and Pharmacodynamics of Ponesimod, a selective S1P1 receptor modulator, in the first-in-human study. Br. J. Clin. Pharmacol. doi:10.1111/bcp.12129 (2013) ( Epub ahead of print).
  • Hartung J, Peach R, Boehm M et al. Safety and tolerability of orally administered RPC1063, a novel S1P1 receptor agonist, in healthy adult volunteers. Presented at: 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Lyon, France, 10–13 October 2012 ( Abstract P457).
  • Moberly JB, Ford DM, Zahir H et al. Pharmacological effects of CS-0777, a selective sphingosine 1-phosphate receptor-1 modulator: results from a 12-week, open-label pilot study in multiple sclerosis patients. J. Neuroimmunol. 246(1–2), 100–107 (2012).
  • Sorensen PS, Drulovic J, Hardova E et al. Magnetic resonance imaging (MRI) efficacy of ofatumumab in relapsing-remitting multiple sclerosis—results of a phase II study. Presented at: 63rd Annual Meeting of the American Academy of Neurology. Honolulu, Hawaii, USA, 9–16 April 2011.
  • Reichert JM. Antibodies to watch in 2013: Mid-year update. MAbs 5(4):513–517 (2013).
  • Petermann F, Korn T. Cytokines and effector T cell subsets causing autoimmune CNS disease. FEBS Lett. 585(23), 3747–3757 (2011).
  • Patel DD, Lee DM, Kolbinger F, Antoni C. Effect of IL-17A blockade with secukinumab in autoimmune diseases. Ann. Rheum. Dis. 72( Suppl. 2), ii116–ii123 (2013).
  • Hueber W, Patel DD, Dryja T et al. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci. Transl. Med. 2(52), 52ra72 (2010).
  • Papp KA, Langley RG, Sigurgeirsson B et al. Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study. Br. J. Dermatol. 168(2), 412–421 (2013).
  • Havrdova E. Secukinumab in multiple sclerosis. A Phase II study. Presented at: 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Lyon, France, 10–13 October 2012 ( Abstract P168).
  • Rudick R, Wiendl H, Steinman L et al. Efficacy and safety of AIN457 (secukinumab) in patients with relapsing multiple sclerosis: design of an adaptive dose-ranging phase 2 study. Presented at: 29th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Copenhagen, Denmark, 2–5 October 2013 ( Abstract P1103).
  • Luckey A, Anderson TJ, Silverman MH. A phase II, open-label, dose escalation of intravenous MIS416 in progressive multiple sclerosis. Presented at: 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Lyon, France, 10–13 October 2012 ( Abstract P1095).
  • Kovalchin J, Krieger J, Genova M et al. Results of a phase I study in patients suffering from secondary-progressive multiple sclerosis demonstrating the safety of the amino acid copolymer PI-2301 and a possible induction of an anti-inflammatory cytokine response. J. Neuroimmunol. 225(1–2), 153–163 (2010).
  • Kovalchin J, Krieger J, Collins K et al. Safety, pharmacokinetic, and pharmacodynamic evaluations of PI-2301, a potent immunomodulator, in a first-in-human, single-ascending-dose study in healthy volunteers. J. Clin. Pharmacol. 51(5), 649–660 (2011).
  • Yadav V, Bourdette DN, Bowen JD et al. Recombinant T-cell receptor ligand (RTL) for treatment of multiple sclerosis: a double-blind, placebo-controlled, Phase 1, dose-escalation study. Autoimmune Dis. 2012, 954739 (2012).
  • Mi S, Blake Pepinsky R, Cadavid D. Blocking LINGO-1 as a therapy to promote CNS repair: from concept to the clinic. CNS Drugs 27(7), 493–503 (2013).
  • Tran J, Palaparthy R, Zhao J et al. Safety, tolerability and pharmacokinetics of the anti-LINGO-1 monoclonal antibody BIIB033 in healthy volunteers and subjects with multiple sclerosis. Neurology 78( Meeting Abstracts 1), P02.021 (2012).
  • Perron H, Germi R, Bernard C et al. Human endogenous retrovirus type W envelope expression in blood and brain cells provides new insights into multiple sclerosis disease. Mult. Scler. 18(12), 1721–1736 (2012).
  • Kremer D, Schichel T, Förster M et al. HERV-W envelope protein inhibits oligodendroglial precursor cell differentiation. Ann. Neurol. doi:10.1002/ana.23970 (2013) ( Epub ahead of print).
  • Curtin F, Lang AB, Perron H et al. GNbAC1, a humanized monoclonal antibody against the envelope protein of multiple sclerosis-associated endogenous retrovirus: a first-in-humans randomized clinical study. Clin. Ther. 34(12), 2268–2278 (2012).
  • Derfuss T, Curtin F, Guebelin C et al. Safety and pharmacokinetics of GNbAC1, a humanised monoclonal antibody against the multiple sclerosis associated retrovirus envelope protein in patients with multiple sclerosis. Presented at: 29th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Copenhagen, Denmark, 2–5 October 2013 ( Abstract P566).
  • Giraudon P, Vincent P, Vuaillat C et al. Semaphorin CD100 from activated T lymphocytes induces process extension collapse in oligodendrocytes and death of immature neural cells. J. Immunol. 172, 1246–1255 (2004).
  • Fisher T, Reilly C, Winter L et al. Development of anti-SEMA4D monoclonal antibody for the treatment of multiple sclerosis. Presented at: 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Lyon, France, 10–13 October 2012 ( Abstract P963).
  • Rolan P, Gibbons JA, He L et al. Ibudilast in healthy volunteers: safety, tolerability and pharmacokinetics with single and multiple doses. Br. J. Clin. Pharmacol. 66(6), 792–801 (2008).
  • Barkhof F, Hulst HE, Drulovic J, Uitdehaag BM, Matsuda K, Landin R; MN166–001 Investigators. Ibudilast in relapsing-remitting multiple sclerosis: a neuroprotectant? Neurology 74(13), 1033–1040 (2010).
  • Shirani A, Zhao Y, Karim ME et al. Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis. JAMA 308(3), 247–256 (2012).
  • Degenhardt A, Ramagopalan SV, Scalfari A, Ebers GC. Clinical prognostic factors in multiple sclerosis: a natural history review. Nat. Rev. Neurol. 5(12), 672–682 (2009).
  • Confavreux C, Vukusic S. Accumulation of irreversible disability in multiple sclerosis: from epidemiology to treatment. Clin. Neurol. Neurosurg. 108(3), 327–332 (2006).
  • Comi G, Colombo B, Martinelli V. Prognosis-modifying therapy in multiple sclerosis. Neurol. Sci. 21( 4 Suppl. 2), S893–S899 (2002).
  • Deiss A, Brecht I, Haarmann A, Buttmann M. Treating multiple sclerosis with monoclonal antibodies: a 2013 update. Expert Rev. Neurother. 13(3), 313–335 (2013).
  • Brennan FR, Morton LD, Spindeldreher S et al. Safety and immunotoxicity assessment of immunomodulatory monoclonal antibodies. MAbs 2(3), 233–255 (2010).
  • Bloomgren G, Richman S, Hotermans C et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N. Engl. J. Med. 366(20), 1870–1880 (2012).
  • Riminton DS, Hartung HP, Reddel SW. Managing the risks of immunosuppression. Curr. Opin. Neurol. 24(3), 217–223 (2011).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.